Peter Attia· MD
biochemically and there are people who are looking at for instance using a metabolite of I began nor ibogaine which may mitigate some of the risks
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
biochemically and there are people who are looking at for instance using a metabolite of I began nor ibogaine which may mitigate some of the risks
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
we're in the process of working with a company that's developing a derivative of ibogaine called noribogaine which may be less cardiotoxic